OLYMPIA-1: A phase 3 trial of odronextamab in people with untreated follicular lymphoma

This trial is testing the treatment odronextamab in adults with follicular lymphoma who have not received any previous treatment. 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT06091254
 

Trial aim and background  

The aim of this trial is to find out how the medication odronextamab compares to current standard of care in follicular lymphoma, which is rituximab and chemotherapy.

It will be made up of two parts: part 1 is to see how safe and well tolerated the treatment is, and part 2 will see how it compares to current treatment.

Amongst other things the study aims to look at:

  • What side effects the treatment has
  • Whether your body makes antibodies against the treatment
  • Whether the treatment impacts on your quality of life

Odronextamab is a bispecific antibody. This is a type of targeted treatment which sticks to two different target proteins, one on lymphoma cells and one on healthy T cells. This helps the T cells find and destroy the lymphoma cells.

Who can enter 

People over 18 with follicular lymphoma who require treatment may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • Beatson West of Scotland Cancer Centre, Glasgow
  • Queens Hospital - Barking, Havering and Redbridge University Hospitals NHS Trust, Romford
  • Royal Cornwall Hospital NHS Trust, Truro
  • Derriford Hospital, Plymouth
  • Norfolk and Norwich University Hospital, Norwich

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06091254

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.